Chronic treatment of silymarin improves hyperalgesia and motor nerve conduction velocity in diabetic neuropathic rat

Phytotherapy Research

Volumn 24, Issue 8, 2010, Pages 1120-1125

  Baluchnejadmojarad, Tourandokht ^a   Roghani, Mehrdad ^b   Khastehkhodaie, Zeynab ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHED UNIVERSITY   (Iran)

Author keywords

Diabetic neuropathy; Hyperalgesia; Silymarin

Indexed keywords

MALONALDEHYDE; SALICYLATE SODIUM; SILYMARIN; SUPEROXIDE DISMUTASE; ANTIOXIDANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG EFFECT; DRUG EFFICACY; HYPERALGESIA; LONG TERM CARE; MALE; MOTOR NERVE CONDUCTION; NONHUMAN; OXIDATIVE STRESS; RAT; SCIATIC NERVE; TREATMENT OUTCOME; WISTAR ALBINO GLAXO RAT; ANIMAL; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DRUG EFFECTS; METABOLISM; NERVE CONDUCTION; WISTAR RAT;

RATTUS;

ANIMALS; ANTIOXIDANTS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; HYPERALGESIA; MALE; MALONDIALDEHYDE; NEURAL CONDUCTION; OXIDATIVE STRESS; RATS; RATS, WISTAR; SILYMARIN; SODIUM SALICYLATE; SUPEROXIDE DISMUTASE;

EID: 77955638295     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3078     Document Type: Article

References (53)

1. Anjaneyulu M, Chopra K. 2004. Quercetin attenuates thermal hyperalgesia and cold allodynia in STZ-induced diabetic rats. Indian J Exp Biol 42: 766-769. (Pubitemid 39059184)
2. Burnard SL, McMurchie EJ, Leifert WR, Patten GS, Muggli R, Raederstorff D, Head RJ. 1998. Cilazapril and dietary gamma-linolenic acid prevent the deficit in sciatic nerve conduction velocity in the streptozotocin diabetic rat. J Diabetes Complicat 12: 65-73. (Pubitemid 28156436)
3. Cameron NE, Cotter MA. 1999. Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes. Diabetes Res Clin Pr 45: 137-146.
4. Cameron NE, Cotter MA, Horrobin DH, Tritschler HJ. 1998. Effects of alpha-lipoic acid on neurovascular function in diabetic rats: interaction with essential fatty acids. Diabetologia 41: 390-399.
5. Ciruela A, Dixon AK, Bramwell S, Gonzalez MI, Pinnock RD, Lee K. 2003. Identification of MEK1 as a novel target for the treatment of neuropathic pain. Brit J Pharmacol 138: 751-756. (Pubitemid 36401513)
6. Coppey LJ, Gellett JS, Davidson EP, Dunlap JA, Yorek MA. 2002. Effect of treating streptozotocin-induced diabetic rats with sorbinil, myoinositol or aminoguanidine on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve. International Journal of Experimental Diabetes Research 3: 21-36.
7. Cotter MA, Jack AM, Cameron NE. 2002. Effects of the protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes. Clin Sci (London) 103: 311-321.
8. Cotter MA, Love A, Watt MJ, Cameron NE, Dines KC. 1995. Effects of natural free radical scavengers on peripheral nerve and neurovascular function in diabetic rats. Diabetologia 38: 1285-1294.
9. Courteix C, Eschalier A, Lavarenne J. 1993. Streptozotocin-induced diabetic rats: behavioral evidence for a model of chronic pain. Pain 53: 81-88. (Pubitemid 23137271)
10. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. 2000. Endothelial dysfunction in diabetes. Brit J Pharmacol 130: 963-974.
11. Dehmlow C, Murawski N, de Groot H. 1996. Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. Life Sci 58: 1591-1600. (Pubitemid 26129234)
12. Dobretsov M, Hastings SL, Stimers JR, Zhang JM. 2001. Mechanical hyperalgesia in rats with chronic perfusion of lumbar dorsal root ganglion with hyperglycemic solution. J Neurosci Meth 110: 9-15. (Pubitemid 32846533)
13. Dubuisson D, Dennis SG. 1977. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine and brain stem stimulation in rats and cats. Pain 4: 161-174. (Pubitemid 8234766)
14. Feillet-Coudray C, Rock E, Coudray C, Grzelkowska K, Azais-Braesco V, Dardevet D, Mazur A. 1999. Lipid peroxidation and antioxidant status in experimental diabetes. Clinica Chemica Acta 284: 31-34. (Pubitemid 29324863)
15. Feng CG, Zhang LX, Liu X. 2005. Progress in research of aldose reductase inhibitors in traditional medicinal herbs. Zhongguo Zhong Yao Za Zhi 30: 1496-1500. (Pubitemid 44795765)
16. Fox A, Eastwood C, Gentry C, Manning D, Urban L. 1999. Critical evaluation of the streptozotocin model of painful diabetic neuropathy in the rat. Pain 81: 307-316. (Pubitemid 29257901)
17. Freshwater JD, Svensson CI, Malmberg AB, Calcutt NA. 2002. Elevated spinal cyclooxygenase and prostaglandin release during hyperalgesia in diabetic rats. Diabetes 51: 2249-2255.
18. Gullapalli S, Gurumoorthy K, Kaul CL, Ramarao P. 2002. Role of L-type Ca2+ channels in attenuated morphine antinociception in streptozotocin-diabetic rats. Eur J Pharmacol 435: 187-194. (Pubitemid 34131699)
19. Head RJ, McLennan PL, Raederstorff D, Muggli R, Burnard Sl, McMurchie EJ. 2000. Prevention of nerve conduction deficit in diabetic rats by polyunsaturated fatty acids. Am J Clin Nutrit 71: 386S-392S. (Pubitemid 30046147)
20. Huseini HF, Larijani B, Heshmat R, Fakhrzadeh H, Radjabipour B, Toliat T, Raza M. 2006. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytotherapy Res 20: 1036-1039. (Pubitemid 44951705)
21. Imánek V, Kottová N, Bartek J, Psotová J, Kosina P, Balejová L. 2001. Extract from Silybum marianum as nutraceutical: a double blind placebo-controlled study in healthy young men. Czech Journal of Food Sciences 19: 106-110.
22. Jensen TS, Baron R. 2003. Translation of symptoms and signs into mechanisms in neuropathic pain. Pain 102: 1-8. (Pubitemid 36298856)
23. Karimi G, Ramezani M, Tahoonian Z. 2005. Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evidence-based Complementary and Alternative Medicine 2: 383-386. (Pubitemid 41253351)
24. Kim HK, Kim MJ, Lyu ES, Shin DH. 2009. Improvement of diabetic complication by hydrangea dulcis folium in streptozotocin-induced diabetic rats. Biol Pharm Bull 32: 153-156.
25. Láng I, Deák G, Müzes G, Prónai, L, Fehér J. 1993. Effect of the natural bioflavonoid antioxidant silymarin on superoxide dismutase (SOD) activity and expression in vitro. Biotechnol Ther 4: 263-270. (Pubitemid 23333072)
26. Malcangio M, Tomlinson DR. 1998. A pharmacologic analysis of mechanical hyperalgesia in streptozotocin-diabetic rats. Pain 76: 151-157. (Pubitemid 28304951)
27. Mizisin AP, Steinhardt RC, Brien JS, Calcut NA. 2001. TX14(A), a prosaposin-derived peptide, reverses established nerve disorders in streptozotocin-diabetic rats and prevents them in galactose-fed rats. J Neuropath Exp Neur 60: 953-960.
28. Montvale NJ. 2000. PDR for herbal medicines Medical Economics Company; Montvale. 516-520.
29. Müzes G, Deák G, Láng I, Nékám K, Niederland V, Fehér J. 1990. Effect of silymarin (Legalon) therapy on the antioxidant defense mechanism and lipid peroxidation in alcoholic liver disease (double blind protocol). Orvosi Hetilap 131: 863-866.
30. Nickander KK, McPhee BR, Low PA, Tritschler H. 1996. Alphalipoic acid: antioxidant potency against lipid peroxidation of neural tissues in vitro and implications for diabetic neuropathy. Free Rad Biol Med 21: 631-639. (Pubitemid 26331093)
31. Nourooz-Zadeh J, Rahimi A, Tajaddini-Sarmadi J, Tritschler H, Rosen, P, Halliwell B, Betteridge DJ. 1997. Relationships between plasma measures of oxidative stress and metabolic control in NIDDM. Diabetologia 40: 647-653. (Pubitemid 27288109)
32. Oates PJ, Mylari BL. 1999. Aldose reductase inhibitors: therapeutic implications for diabetic complications. Expert Opinion on Investigational Drugs 8: 2095-2119.
33. Obrosova IG. 2003. Update on the pathogenesis of diabetic neuropathy. Current Diabetes Reports 3: 439-445.
34. Obrosova IG, Huyssen VC, Fathallah I, Cao A, Stevens MJ, Greene DA. 2002. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J 16: 123-125.
35. Ohi T, Saita K, Furukawa S, Ohta M, Hayashi K, Matsukura S. 1998. Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor. ExperNeurol 151: 215-220. (Pubitemid 28285901)
36. Pepping J. 1999. Milk thistle: Silybum marianum. Am J Health Syst Pharm 56: 1195-1197.
37. Raccah D, Coste T, Cameron NE, Dufayet D, Vague P, Hohman TC. 1998. Effect of the aldose reductase inhibitor tolrestat on nerve conduction velocity, Na/K ATPase activity, and polyols in red blood cells, sciatic nerve, kidney cortex, and kidney medulla of diabetic rats. J Diabetes Complicat 12: 154-162. (Pubitemid 28241440)
38. Rosland JH, Tjolsen A, Maehle B, Hole K. 1990. The formalin test in mice-effect of formalin concentration. Pain 42: 235-242.
39. Rutledge LP, Ngong JM., Kuperberg JM, Samaan SS, Soliman KF, Kolta MG. 2002. Dopaminergic system modulation of nociceptive response in long-term diabetic rats. Pharmacol Biochem Be 74: 1-9.
40. Sen CK. 1995. Oxygen toxicity and antioxidants: state of the art. Indian J Physiol Pharmacol 39: 177-196.
41. Sharma SS, Sayyed SG. 2006. Effects of trolox on nerve dysfunction, thermal hyperalgesia and oxidative stress in experimental diabetic neuropathy. Clin Exper Pharmacol Physiol 33: 1022-1028.
42. Sharma S, Kulkarni SK, Chopra K. 2006. Resveratrol, a polyphenolic phytoalexin attenuates thermal hyperalgesia and cold allodynia in STZ-induced diabetic rats. Indian J Exper Biol 44: 566-569. (Pubitemid 44049409)
43. Shibata M, Ohkubo T, Takahashi H, Inoki R. 1989. Modified formalin test: characteristic biphasic pain response. Pain 38: 347-352. (Pubitemid 19251258)
44. Sima AA, Sugimoto K. 1999. Experimental diabetic neuropathy: an update. Diabetologia 42: 773-788.
45. Sobolová L, Skottová N, Vecera R, Urbánek K. 2006. Effect of silymarin and its polyphenolic fraction on cholesterol absorption in rats. Pharmacol Res 53: 104-112. (Pubitemid 43003476)
46. Soto C, Recoba R, Barrón H, Alvarez C, Favari L. 2003. Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas. Comp Biochem Phys C 136: 205-212. (Pubitemid 37500850)
47. Toleikis PM, Godin DV. 1995. Alteration of antioxidant status in diabetic rats by chronic exposure to psychological stressors. Pharmacol Biochem Be 52: 355-366.
48. van Dam PS. 2002. Oxidative stress and diabetic neuropathy: pathophysiological mechanisms and treatment perspectives. Diabetes-Metab Res 18: 176-184. (Pubitemid 34778380)
49. Velussi M, Cernigoi AM, De Monte A, Dapas F, Caffau C, Zilli M. 1997. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol 26: 871-879. (Pubitemid 27145712)
50. Vincent AM, Russell JW, Low P, Feldman EL. 2004. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocrine Rev 25: 612-628. (Pubitemid 39096072)
51. Wellington K, Jarvis B. 2001. Silymarin: a review of its clinical properties in the management of hepatic disorders. Bio- Drugs 15: 465-489.
52. Wild S, Roglic G, Green A, Sicree R, King H. 2004. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053. (Pubitemid 38579764)
53. Wohaieb SA, Godin DV. 1987. Alterations in free radical tissue-defense mechanisms in streptozocin-induced diabetes in rat. Effects of insulin treatment. Diabetes 36: 1014-1018.